Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society 68th Annual Scientific Meeting
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
Blue Jay Gold Announces Closing of Private Placement With Ocean Partners for Proceeds of $3.0 Million
Ucore Receives Louisiana Air Permit Covering Full 9,600 tpa Build-Out of Its Strategic Metals Complex
QIMC Sets Out Five-Phase Plan to Test Hydrogen Extraction at Bennett Hill, Nova Scotia, on the Path to Commercialization
Sankamap Completes Latest Drill Hole as Part of Broader Exploration Program at Kuma Copper-Gold Project
Metalsource Mining Inc. Advancing Historic Silver Mine with Modern Drilling, Aggressive Exploration Campaign